Pharmaceutical biocatalysis

Biocatalysis has emerged as an important tool for the enantioselective synthesis of chiral pharmaceutical intermediates and several review articles have been published in recent years [133-137]. For example, quinuclidinol is a common pharmacophore of neuromodulators acting on muscarinic receptors (Figure 6.50). (JJ)-Quinudidin-3-ol was prepared via Aspergillus melleus protease-mediated enantioselective hydrolysis of the racemic butyrate [54,138]. Calcium hydroxide served as a scavenger of butyric acid to prevent enzyme inhibition and the unwanted (R) enantiomer was racemized over Raney Co under hydrogen for recycling. 

Gotor-Fernandez, V., ReboDedo, F. and Gotor, V. (2007) Preparation of chiral pharmaceuticals through enzymatic acylation of alcohols and amines, in Biocatalysis in the Pharmaceutical and Biotechnology Industry, (ed. R.M. Patel), Dekker, Taylor and Francis, New York, Chapter 7, pp. 203-248. 

Patel, R.N. (2007) Biocatalysis in the Pharmaceutical and Biotechnology Industries, CRC Press, Boca Raton. 

Patel, R.N. (ed.) (2007) Biocatalysis in the Pharmaceutical and Biotechnology Industries, CRC Press, Boca Raton. Aehle, W. (ed.) (2007) Enzymes in Industry, 3rd edn, Wiley-VCH GmbH Co., KGaA., Weinheim. 

BIOCATALYSIS FOR THE PHARMACEUTICAL INDUSTRY Discovery, Development, and Manufacturing... 

Biocatalysis for the pharmaceutical industry discovery, development, and manufacturing/Junhua Tao, Guo-Qiang Lin, Andreas Liese. p. cm. 

Green Chemistry with Biocatalysis for Production of Pharmaceuticals 305... 

Consequently, many successful stories and a number of reviews have been reported recently in developing biocatalysis for the pharmaceutical industry, across drug discovery, development, and manufacturing. The book is dedicated to these advances, and divided into four parts ... 

Biocatalysis for the Pharmaceutical Industry edited by Junhua Tao, Guo-Qiang Lin, and Andreas Liese 2009 John Wiley Sons Asia (Pte) Ltd... 

The complexity of today s pharmaceutical compounds and an increasing awareness of the environmental impact of traditional chemical syntheses have opened the door to biocatalysis. Directed evolution is an integral tool in the development of synthetic enzymes, ensuring they are suitable for use in an industrial setting. The past success of this approach indicates that it will continue to provide many examples of safe and efficient production of chemical intermediates and medical compounds. 

Bommarius, A.S., Scharm, M. and Drauz, K. (1998) Biocatalysis to amino acid-based chiral pharmaceuticals -examples and perspectives. Journal of Molecular Catalysis B, Enzymatic, 5, 1-11. 

Woodley, J.M. (2008) New opportunities for biocatalysis making pharmaceutical processes greener. Trends in Biotechnology, 26 (6), 321-327. 

Zaks, A. and Dodds, D.R. (1997) Application of biocatalysis and biotransformations to the synthesis of pharmaceuticals. Drug Discovery Today, 2, 513-531. 

Azerad, R. (2007) Biotransformation of natural or synthetic compounds for the generation of molecular diversity, in Biocatalysis in the Pharmaceutical and Biotechnology Industries (ed. R.N. Patel), CRC Press Boca Raton, FL, pp. 273-297. 

Hamann, M.T. (2003) Enhancing marine natural product structural diversity and bioactivity through semisynthesis and biocatalysis. Current Pharmaceutical Design, 9, (11) 879-889. 

---